Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001178913-25-001274
Filing Date
2025-04-10
Accepted
2025-04-10 17:25:51
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10558
  Complete submission text file 0001178913-25-001274.txt   12439
Mailing Address 4 ITZHAK SADE BUILDING A 29TH FLOOR TEL AVIV L3 6777520
Business Address 4 ITZHAK SADE BUILDING A 29TH FLOOR TEL AVIV L3 6777520 972-3-6845535
SPHERA FUNDS MANAGEMENT LTD. (Filed by) CIK: 0001496201 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3
Type: SCHEDULE 13G/A

Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Subject) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-86953 | Film No.: 25829308
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)